D
Arbutus Biopharma Corporation ABUS
$3.13 -$0.01-0.32% NASDAQ
Recommendation
Prev Close
$3.14
Volume
894,110
Avg Vol (90D)
927,030
Market Cap
$601.40M
Dividend & Yield
--
52-Week Range
$2.71 - $4.73
P/E (TTM)
--
EPS (TTM)
-$0.4075
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Arbutus Biopharma's AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment
7/18/2025 - TipRanks Financial Blog
Arbutus Biopharma (ABUS, $3.14) Stochastic Oscillator left the oversold zone on July 17, 2025
7/18/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.13) entered Downtrend as Momentum indicator drops below 0 level on Jul 16, 2025
7/17/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.24) Stochastic Oscillator left the oversold zone on July 03, 2025
7/4/2025 - Tickeron - Technical Analysis
Arbutus Biopharma (ABUS, $3.18) RSI Indicator left the oversold zone on July 01, 2025
7/2/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.13) RSI Indicator left the oversold zone on June 27, 2025
6/28/2025 - Tickeron - Stocks
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - Time to Sell?
6/26/2025 - MarketBeat
Arbutus Biopharma (ABUS, $3.34) price exceeded its 50-day Moving Average on June 25, 2025
6/26/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.37) Stochastic Oscillator left the oversold zone on June 24, 2025
6/25/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug ABUS Stock News
6/25/2025 - GuruFocus
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB
6/25/2025 - The Fly
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
6/25/2025 - Globe Newswire
Arbutus Biopharma (ABUS, $3.41) entered Downtrend as Momentum indicator drops below 0 level on Jun 23, 2025
6/24/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.43) Moving Average Convergence Divergence (MACD) Histogram turned negative on June 20, 2025
6/21/2025 - Tickeron - Stocks
Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
6/7/2025 - MarketBeat
Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
6/5/2025 - MarketBeat
Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
5/30/2025 - MarketBeat
Woodline Partners LP Has $3.18 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
5/25/2025 - Ticker Report
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Two Seas Capital LP
5/23/2025 - MarketBeat
Arbutus Biopharma Co. (NASDAQ:ABUS) is Whitefort Capital Management LP's Largest Position
5/22/2025 - MarketBeat
Arbutus Biopharma (ABUS, $3.21) Stochastic Oscillator left the oversold zone on May 20, 2025
5/21/2025 - Tickeron - Stocks
Component Price Targets Imply 28% Gains Ahead For Russell 2000
5/15/2025 - ETF Channel
Arbutus Biopharma Co. (NASDAQ:ABUS) Position Trimmed by LMR Partners LLP
5/15/2025 - Ticker Report
Hudson Bay Capital Management LP Boosts Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
5/15/2025 - MarketBeat
Arbutus Biopharma (ABUS) Reports Mixed Q1 Results
5/14/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$6.40M
EBITDA (TTM)
-$66.18M
EBIT (TTM)
-$67.54M
Net Income (TTM)
-$76.57M
Balance Sheet
Total Assets (Q)
$117.01M
Total Debt (Q)
$5.60M
Total Liabilities (Q)
$37.85M
Book Value Per Share (Q)
$0.4134
Cash Flow
Cash from Operations (TTM)
-$58.95M
Cash from Investing (TTM)
$22.60M
Cash from Financing (TTM)
$30.35M
Net Change in Cash (TTM)
-$6.03M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
0.45
7-Day Total Return
-6.29%
30-Day Total Return
-8.21%
60-Day Total Return
-1.88%
90-Day Total Return
0.64%
Year to Date Total Return
-4.86%
1-Year Total Return
-15.18%
2-Year Total Return
41.63%
3-Year Total Return
27.76%
5-Year Total Return
5.39%
52-week Low
Apr 09, 2025 - $2.71
52-week High
Sep 09, 2024 - $4.73
Valuation
Market Cap
$601.40M - Small Cap
Enterprise Value
$494.29M
Price/Sales (TTM)
93.73
Price/Book (Q)
7.60
Dividends and Shares
Shares Outstanding
190.71
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.arbutusbio.com
Phone Number
267 469 0914
Address
701 Veterans Circle
Warminster, PA 18974
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline... more
NASDAQ 07/18/2025 4:00PM Eastern Quotes delayed